BRIEF—RedHill defends against generics with new research

RedHill Biopharma has published new data for its antibiotic Talicia (omeprazole/amoxicillin/rifabutin), focused on differentiating the brand from generic alternatives.

As well as showing non-bioequivalence with copycat alternatives, the published data show that a three-times daily regimen is as effective as a stricter once-per-eight-hours regimen.

The more patient-friendly dosing schedule is thought likely to support adherence.

The research has been published in the Journal Alimentary Pharmacology and Therapeutics (AP&T) and presented at Digestive Disease Week (DDW).

Colin Howden, a professor at the University of Tennessee, said: “Given the potential for antibiotic resistance and treatment failure, the non-equivalence of generics shown by these data should be kept front of mind when prescribing first-line therapy for H. pylori eradication.”